Literature DB >> 3927837

In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid.

I Shalit, D F Welch, V H San Joaquin, M I Marks.   

Abstract

Intraperitoneal antibiotics are used to treat Pseudomonas aeruginosa peritonitis, a serious complication of continuous ambulatory peritoneal dialysis. However, P. aeruginosa killing is often inefficient despite low MBCs. Broth dilution MIC/MBC and time kill curves of tobramycin, amikacin, netilmicin, azlocillin, piperacillin, ceftazidime, cefsulodin, and ciprofloxacin were determined in peritoneal dialysis fluid (PDF), buffered PDF, fluid recovered from patients on continuous ambulatory peritoneal dialysis (RPF), and cation-supplemented Mueller-Hinton broth. MBCs of all antibiotics were 8 to 16 times greater in PDF and RPF than in Mueller-Hinton broth or buffered PDF. Use of the time kill curve technique and Mueller-Hinton broth showed that aminoglycosides killed greater than or equal to 99.9% of P. aeruginosa at 1 h, ciprofloxacin killed greater than or equal to 99.9% at 2 h, and beta-lactams killed greater than or equal to 99.9% at 6 h. In contrast, killing was not demonstrated in PDF by any drug at 6 h and by aminoglycosides only at 24 h. Bactericidal activity was optimal in RPF for ciprofloxacin at 1 h and for aminoglycosides at 2 h; bactericidal activity was not demonstrated in RPF with any beta-lactam (no kill by penicillins; less than 99% kill by cephalosporins). Slow bacterial growth, increased protein binding, and glucose concentrations and other inhibitors may interfere with beta-lactam activity in RPF. These considerations and reported clinical failures and toxicity of aminoglycoside therapy warrant further study of quinolones and drug combinations in P. aeruginosa peritonitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927837      PMCID: PMC180184          DOI: 10.1128/AAC.27.6.908

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  MECHANISM OF DEGRADATION OF PENICILLIN G IN ACIDIC SOLUTION.

Authors:  M A SCHWARTZ
Journal:  J Pharm Sci       Date:  1965-03       Impact factor: 3.534

2.  Inhibition of the antibacterial activity of gentamicin by urine.

Authors:  J N Minuth; D M Musher; S B Thorsteinsson
Journal:  J Infect Dis       Date:  1976-01       Impact factor: 5.226

3.  The mode of action of antibiotics on gram-negative bacilli.

Authors:  V Lorian
Journal:  Arch Intern Med       Date:  1971-10

4.  Effect of peritoneal dialysis solution on the antimicrobial activity of cephalosporins.

Authors:  D H Appleby; J F John
Journal:  Nephron       Date:  1982       Impact factor: 2.847

5.  Peritonitis in continuous ambulatory peritoneal dialysis.

Authors:  R Gokal
Journal:  J Antimicrob Chemother       Date:  1982-06       Impact factor: 5.790

6.  Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro.

Authors:  L Tybring; N H Melchior
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

7.  Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis.

Authors:  R Maiorca; A Cantaluppi; G C Cancarini; A Scalamogna; R Broccoli; G Graziani; S Brasa; C Ponticelli
Journal:  Lancet       Date:  1983-09-17       Impact factor: 79.321

8.  Pseudomonas peritonitis and continuous ambulatory peritoneal dialysis.

Authors:  R Krothapalli; W B Duffy; C Lacke; W Payne; H Patel; V Perez; H O Senekjian
Journal:  Arch Intern Med       Date:  1982-10

9.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

10.  Peritonitis in children undergoing continuous ambulatory peritoneal dialysis.

Authors:  R N Fine; I B Salusky; T Hall; L Lucullo; S C Jordan; R B Ettenger
Journal:  Pediatrics       Date:  1983-05       Impact factor: 7.124

View more
  16 in total

1.  In vitro antistaphylococcal activity of teicoplanin and ciprofloxacin in peritoneal dialysis effluent.

Authors:  D Guay; R Klicker; T Pence; P Peterson
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

2.  In vitro activity of four new quinolones in Mueller-Hinton broth and peritoneal dialysis fluid.

Authors:  C Weissauer-Condon; I Engels; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

3.  Effect of pathological changes of pH, pO2 and pCO2 on the activity of antimicrobial agents in vitro.

Authors:  C König; H P Simmen; J Blaser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

4.  In vitro bactericidal activities of gentamicin, cefazolin, and imipenem in peritoneal dialysis fluids.

Authors:  D C Halstead; J Guzzo; J A Giardina; A E Geshan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

6.  Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.

Authors:  Christine Strijack; Godfrey K M Harding; Robert E Ariano; Sheryl A Zelenitsky
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis.

Authors:  M Kussmann; L Schuster; M Zeitlinger; P Pichler; G Reznicek; M Wiesholzer; H Burgmann; W Poeppl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-04       Impact factor: 3.267

8.  Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; John R Hotchkiss; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.

Authors:  Manuel Kussmann; Linda Schuster; Sarah Wrenger; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Perit Dial Int       Date:  2016-09-28       Impact factor: 1.756

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.